News & Announcements

Information About Coronavirus Disease 2019 (COVID-19)

Division of HIV and STD Programs Temporary Phone Directorythis temporary phone directory includes contact information for DHSP staff during the COVID-19 outbreak.

Additional Resources:

  • Interim Guidance for COVID-19 and Persons with HIV is now available. The guidance, which was developed collectively by the HHS Antiretroviral and Opportunistic Infections Guidelines Panels, working groups of the Office of AIDS Research Advisory Council, is intended for health care providers and persons living with HIV in the United States.
  • HRSA is working to keep Ryan White HIV/AIDS Program recipients, subrecipients, and partners updated on the latest information regarding COVID-19.  As part of that effort, HRSA’s HIV/AIDS Bureau (HAB) has launched a Frequently Asked Question (FAQ) webpage on the HAB website, which HAB is monitoring and updating as new information is made available.
  • Disease Control and Prevention (CDC) has made available a Frequently Asked Questions (FAQs) about HIV and coronavirus disease 2019 (COVID-19). The new resource addresses concerns related to COVID-19 and HIV and highlights how people with HIV can protect their health.
  • NASTAD has compiled a summary of other COVID-19 related resources and updates on a newly launched "Updates and Resources" website.

HIV STD Law Updates

In 2018, the Michigan Department of Health and Human Services (MDHHS) worked with the Michigan Legislature, HIV advocates, and HIV service providers to amend the Public Health Code statutes related to HIV. Changes include an updated HIV disclosure law, increased perinatal HIV/STD/Hepatitis B testing for at-risk women, reduced requirements for HIV testing consent requirements, and modified HIV reporting and partner service requirements. Through this work, the health code now reflects the advancements in HIV science and the evolution of our processes and practices.

To highlight the changes for all statutes, MDHHS has created a summary document to assist in understanding the updates and the way they may influence your work in testing and treating HIV and other STDs. MDHHS asks our partners to familiarize themselves with the changes and to share the information with colleagues and medical professionals to adopt these changes as rapidly as possible. 

Clinical Alerts

Chlamydia and Gonorrhea Expedited Partner Therapy (EPT): Michigan Public Act 525 of 2014 (MCL 333.5110) authorized the use of expedited partner therapy (EPT) for certain sexually transmitted diseases as designated by the state health department. In January 2015, the Michigan Department of Health and Human Services designated chlamydia and gonorrhea as diseases for which the use of EPT is appropriate.

Michigan HIV Consultation Program: The Michigan HIV Consultation Program is set up to answer questions from Michigan healthcare professionals regarding HIV disease management; HIV drug-drug interactions; HIV occupational and non-occupational post-exposure prophylaxis (PEP and nPEP); HIV pre-exposure prophylaxis (PrEP); and perinatal HIV treatment. Providers with urgent questions can use the 24-hour consultation line at 313-575-0332.

Tools You Can Use

New information sheets about Syringe Services Programs (SSP) are now available from our partners in Viral Hepatitis:

What's New Around the State

Detroit Public Health STD Clinic Open: The Detroit Public Health STD Clinic is open for testing and treatment. Medicaid and most other insurances are accepted. If you don't have insurance, the clinic offers STD and HIV testing and treatment at little or no cost, regardless of your ability to pay. The clinic offers medical advice, guidance, and new treatments like HIV PrEP. Services are offered on either a walk-in or appointment basis.

  • Clinic Hours
    8:00 a.m. - 4:30 p.m. (M, Tu, Th, F)
    8:00 a.m. - 6:30 p.m. (W)

 

Undetectable = Untransmittable (U=U)MDHHS supports Undetectable = Untransmittable HIV Prevention Campaign: MDHHS has joined the Centers for Disease Control and Prevention (CDC), the National Alliance of State and Territorial AIDS Directors (NASTAD), NAM, and other leaders in the fight to end the HIV epidemic by supporting the Prevention Access campaign Undetectable Equals Untransmittable (U=U).

Based on the emerging research, the scientific consensus is that a person living with HIV taking antiretroviral therapy (ART) as prescribed with an undetectable viral load in their blood sample for at least six months has a negligible risk of transmitting HIV sexually. Viral load refers to the amount of HIV in a blood sample of a person living with HIV. Most often, the higher the viral load, the greater the likelihood an individual with HIV will transmit HIV. ART must be taken daily to achieve viral suppression and maintain untransmittable status.

 

Return to HIV, STDs and Viral Hepatitis in Michigan home page